Ignite Creation Date:
2025-12-24 @ 7:37 PM
Ignite Modification Date:
2026-01-02 @ 1:05 AM
Study NCT ID:
NCT00225303
Status:
COMPLETED
Last Update Posted:
2011-05-19
First Post:
2005-09-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use
Sponsor:
Tibotec Pharmaceuticals, Ireland
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2005-03
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
2006-06
Completion Date Type:
ACTUAL
First Submit Date:
2005-09-12
First Submit QC Date:
None
Study First Post Date:
2005-09-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2011-05-18
Last Update Post Date:
2011-05-19
Last Update Post Date Type:
ESTIMATED